00:00
00:00
00:00
ValiRx Plc - ValiSeek clinical development update

Dr Suzanne Dilly, CEO of ValiSeek Limited, provides an update on the clinical development of ValiSeek which was formed to progress the novel cancer treatment drug, VAL401, towards Clinical Efficacy trials for the treatment of lung cancer and other oncology indications.

Suzanne Dilly
CEO, ValiSeek Limited

Company Events - VALIRX PLC